Press Releases
Philochem will be attending the 10th World ADC Conference in London
Philochem will be attending the 10th World ADC Conference in London (United Kingdom) from March 2 to 5, 2020 10th World ADC London Dr. Samuele Cazzamalli will give a plenary lecture on: “Small...
Read morePhilogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP)...
Read morePhilogen publishes a new study on OncoFAP in Clinical Cancer Research
The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs...
Read morePhilogen announces publication of IL12-7NP2 (an Interleukin-12 fusion protein against Fibroblast Activation Protein) in Journal for Immunotherapy of Cancer.
The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to...
Read moreUpcoming Events
Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)
Philogen will attend the TIDES Europe in Vienna in November 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture entitled “Non-internalizing Small Molecule-Drug Conjugates and...
Read morePhilogen to attend the PEGS Europe 2022 on November 14-16, 2022
Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “Antibody-cytokine fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications”. Please follow the link below for more information...
Read morePast Events
Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)
Philogen attends the SITC Annual Meeting in November 2022. Teresa Hemmerle, PhD, Senior Project Manager, to present an abstract entitled “Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes...
Read morePhilogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs.
Philogen’s management team held a webinar on 29 September 2022 at 16:00 CEST
Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of...
Read more